![Sanofi begins work on succession plan; FDA issues warning letters to Lupin's US, India units | Radio Compass Blog Sanofi begins work on succession plan; FDA issues warning letters to Lupin's US, India units | Radio Compass Blog](https://www.pharmacompass.com/image/news/banner/FDA-raises-cGMP-concerns-at-Lupins-US-India-units-Sanofi-begins-hunt-for-new-CEO-1553493541.jpg)
Sanofi begins work on succession plan; FDA issues warning letters to Lupin's US, India units | Radio Compass Blog
![Teva partners with Just Biotherapeutics, ramping up biologics productivity - BioProcess InsiderBioProcess International Teva partners with Just Biotherapeutics, ramping up biologics productivity - BioProcess InsiderBioProcess International](https://bioprocessintl.com/wp-content/uploads/2019/07/improve-productivity-Tashatuvango.jpg)
Teva partners with Just Biotherapeutics, ramping up biologics productivity - BioProcess InsiderBioProcess International
![FDA Keeps Brand-Name Drugs On A Fast Path To Market ― Despite Manufacturing Concerns | Kaiser Health News FDA Keeps Brand-Name Drugs On A Fast Path To Market ― Despite Manufacturing Concerns | Kaiser Health News](https://khn.org/wp-content/uploads/sites/2/2019/10/branded-drugs-illo-final@3x.png)
FDA Keeps Brand-Name Drugs On A Fast Path To Market ― Despite Manufacturing Concerns | Kaiser Health News
![Celltrion receives FDA 483 with 8 'manageable and correctible' observations - BioProcess InternationalBioProcess International Celltrion receives FDA 483 with 8 'manageable and correctible' observations - BioProcess InternationalBioProcess International](https://bioprocessintl.com/wp-content/uploads/2018/08/korea-flag.jpg)
Celltrion receives FDA 483 with 8 'manageable and correctible' observations - BioProcess InternationalBioProcess International
![Biosimilar… but different: FDA tweaking nonproprietary name guidance - BioProcess InternationalBioProcess International Biosimilar… but different: FDA tweaking nonproprietary name guidance - BioProcess InternationalBioProcess International](https://bioprocessintl.com/wp-content/uploads/2019/03/name-tag-miflippo.jpg)
Biosimilar… but different: FDA tweaking nonproprietary name guidance - BioProcess InternationalBioProcess International
![Teva two: FDA approves Celltrion-made Herceptin biosimilar - BioProcess InternationalBioProcess International Teva two: FDA approves Celltrion-made Herceptin biosimilar - BioProcess InternationalBioProcess International](https://bioprocessintl.com/wp-content/uploads/2018/12/cancer-cell-CIPhotos-300x200.jpg)
Teva two: FDA approves Celltrion-made Herceptin biosimilar - BioProcess InternationalBioProcess International
![Teva settles with Roche to launch first Rituxan biosimilar in US - BioProcess InternationalBioProcess International Teva settles with Roche to launch first Rituxan biosimilar in US - BioProcess InternationalBioProcess International](https://bioprocessintl.com/wp-content/uploads/2018/11/15-zimindmitry.jpg)